TransMedics
The world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation.
Launch date
Employees
Market cap
CAD6.9b
Enterprise valuation
CAD7.1b (Public information from Sep 2024)
Share price
$155.96001 TMDX
Andover Minnesota (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 25.6m | 30.3m | 93.5m | 242m | 443m | 575m | 694m |
| % growth | 9 % | 18 % | 209 % | 159 % | 83 % | 30 % | 21 % |
| EBITDA | (24.7m) | (40.3m) | (32.4m) | (8.0m) | 86.9m | 122m | 170m |
| % EBITDA margin | (96 %) | (133 %) | (35 %) | (3 %) | 20 % | 21 % | 25 % |
| Profit | (28.7m) | (44.2m) | (36.2m) | (25.0m) | 47.2m | 63.9m | 99.7m |
| % profit margin | (112 %) | (146 %) | (39 %) | (10 %) | 11 % | 11 % | 14 % |
| EV / revenue | 17.5x | 15.7x | 19.6x | 11.1x | 13.0x | 10.0x | 8.2x |
| EV / EBITDA | -18.2x | -11.8x | -56.4x | -335.9x | 66.2x | 46.9x | 33.2x |
| R&D budget | 18.8m | 22.3m | 26.8m | 63.3m | - | - | - |
| R&D % of revenue | 73 % | 74 % | 29 % | 26 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$27.9m | Series B | ||
$28.3m | Series C | ||
| N/A | $25.5m | Series D | |
$36.0m | Series E | ||
| N/A | $6.0m | Early VC | |
$36.0m | Debt | ||
| N/A | $20.0m | Debt | |
| N/A | $500k | Debt | |
$51.0m | Growth Equity VC | ||
$12.5m | Growth Equity VC | ||
N/A | Late VC | ||
| N/A | N/A | IPO | |
* | $60.0m | Post IPO Debt | |
* | N/A | $400m | Post IPO Convertible |
| Total Funding | CAD255m | ||
Related Content
Recent News about TransMedics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by TransMedics
Edit
ACQUISITION by TransMedics Aug 2023